MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202641085281 A) filed by Madhankumar C; Dr. S. Kalaiselvan; Mr. V. Tharaneeswaran; Dr. S. Mageswari; Mr. R. Masilamani; and Dr. J. Vidhya on July 12, 2026, for Self-Adaptive Digital Twin Assisted Nanocarrier Platform For Precision Drug Delivery And Real Time Therapeutic Optimization.
Inventors include Dr. S. Kalaiselvan; Mr. V. Tharaneeswaran; Dr. S. Mageswari; Mr. R. Masilamani; and Dr. J. Vidhya.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: PATENT TITLE Self-Adaptive Digital Twin Assisted Nanocarrier Platform for Precision Drug Delivery and Real Time Therapeutic Optimization ABSTRACT The present invention discloses a self-adaptive nanocarrier platform for precision drug delivery and real- time therapeutic optimization. The system comprises biodegradable nanocarriers encapsulating one or more therapeutic agents, physiological sensing modules for continuous patient monitoring, a digital twin framework for creating a virtual representation of patient specific biological conditions, and an adaptive control unit configured to regulate drug release kinetics. Physiological parameters including biomarker concentrations, pH, temperature, oxygen saturation, metabolic indicators, and drug levels are continuously collected and transmitted to the digital twin framework. The virtual model dynamically simulates pharmacokinetic and pharmacodynamic behavior, disease progression, and therapeutic response under varying physiological conditions. Based on the generated predictions, the adaptive control unit modifies the release characteristics of the nanocarriers through stimulus-responsive mechanisms including pH-sensitive, temperature-sensitive, magnetic, enzymatic, ultrasound-responsive, electrical, or light-triggered activation pathways. The closed-loop feedback architecture enables continuous treatment optimization, enhanced drug targeting, improved bioavailability, reduced systemic toxicity, and minimized adverse effects. The invention provides a personalized therapeutic platform capable of adjusting treatment strategies according to individual patient requirements and changing biological conditions. The technology is applicable to cancer therapy, cardiovascular disorders, neurological diseases, infectious disease treatment, diabetes management, regenerative medicine, and advanced precision healthcare systems. The integration of digital twin modeling with responsive nanocarrier technology provides an efficient and scalable solution for next-generation personalized drug delivery and therapeutic management.
Disclaimer: Curated by HT Syndication.
